Jeff Stone, JD, MPH
Outside Intellectual Property Counsel
Mr. Stone counsels national and international medical technology clients on patent strategy, patent prosecution, portfolio development and enforcement, all with an intense focus on building value. This includes building high-value strategic patent portfolios, rendering patent opinions, conducting due diligence, freedom-to-operate analyses and post-grant review (IPR) proceedings. Mr. Stone also advises on the transactional aspects of IP licensing, including joint research, development and commercialization agreements.

Mr. Stone developed an extensive patent portfolio and maintained device-specific freedom-to-operate opinions that supported Abbott’s 2023 acquisition of Cardiovascular Systems, Inc. (“CSI”). Relatedly, Mr. Stone was the architect of 3 IPR proceedings initiated on behalf of CSI targeting foundational aspects of patents owned by Shockwave Medical, Inc. Each IPR was successful, invalidating the patent claims to provide a clear roadmap for marketplace pursuit of intravascular lithotripsy.

In addition, Mr. Stone developed the foundational heart valve patent portfolio and the related freedom-to-operate status for 4C Medical, Inc. (“4C”). In 2025, 4C received an initial $175M (plus potential future milestone payments) from Boston Scientific, together with an option to acquire the company.